Update on GS101 as of January 13, 2026

The company announces that the Investigational New Drug application for its self-developed dupilumab biosimilar, GS101, has received implicit approval from the Center for Drug Evaluation of the National Medical Products Administration. The approval was recorded on January 13, 2026 (Acceptance No.: CXSL2500955). The proposed indication is the treatment of atopic dermatitis.

The release as fetched from its publisher. genscend.com ↗